Efficacy of Pericapsular Nerve Group Block
Launched by THE UNIVERSITY OF HONG KONG · Nov 29, 2021
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new pain relief technique called the Pericapsular Nerve Group Block (PENG) for patients with hip fractures. Hip fractures are common, especially among older adults, and managing pain after surgery is very important. The trial aims to see if the PENG block is more effective than a traditional pain relief method called the fascia iliaca compartment block (FICB) in reducing pain after hip surgery. Researchers will also look at how well patients can move their legs and how strong their muscles are after the procedure.
To participate in this trial, you must be a Chinese adult aged 18 or older, scheduled for hip fracture surgery at Queen Mary Hospital, and able to give informed consent. Some people may not be eligible if they have certain health conditions or allergies, or if they have had significant delays before surgery. If you join the trial, you can expect personalized care and close monitoring of your pain and recovery during your hospital stay. This trial is currently recruiting participants, and your involvement could help improve pain management for future hip fracture patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA I-II
- • Age 18 or above
- • Scheduled for hip fracture corrective surgery in Queen Mary Hospital
- • Chinese patients
- • Able to provide informed oral and written consent
- • Abbreviated Mental Test (AMT) 7 or above
- Exclusion Criteria:
- • Patient refusal
- • ASA III or above
- • Allergy to local anaesthetics, opioids, paracetamol, NSAID including COX-2 inhibitors
- • Operation delayed for more than 2 days on admission
- • Pre-existing peripheral neuropathy or history of stroke
- • Preoperative non-walker
- • Pre-existing osteoarthritis of knee (KL grade 4)
- • Multiple fractures (additional to hip fracture)
- • Sepsis
- • Impaired renal function (Defined as preoperative creatinine level \>120 μmol or eGFR \<50% of normal reference for their age group
- • Patient with coagulopathy (Platelet \< 100 or INR \>1.5)
- • Prior surgery at the inguinal or supra-inguinal area
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Timmy CW Chan, MBBS
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials